NCT01791699View on ClinicalTrials.gov

Moxonidine for Prevention of Post-ablation AFib Recurrences

PHASE4CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

November 30, 2013

Study Completion Date

April 30, 2014

Conditions
Atrial Fibrillation
Interventions
DRUG

Moxonidine

DRUG

Placebo

Trial Locations (3)

10676

Evangelismos General Hospital, Athens

11527

"Athens General Hospital G. Gennimatas", Athens

Unknown

Red Cross Hospital, Athens

All Listed Sponsors
lead

Spyridon Deftereos

OTHER

NCT01791699 - Moxonidine for Prevention of Post-ablation AFib Recurrences | Biotech Hunter | Biotech Hunter